Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923086 | 0.89 | GPR119 (0.43) | TRPV1GPR119STS | |
| SCHEMBL23923085 | 0.84 | GPR119 (0.47) | TRPV1GPR119STS | |
| SCHEMBL23922873 | 0.79 | GPR119 (0.47) | TRPV1GPR119STS | |
| SCHEMBL23923045 | 0.75 | TRPV1 (0.46) | TRPV1GPR119NPC1ALDH1A1MAPT | |
| SCHEMBL23923091 | 0.70 | TRPV1 (0.43) | TRPV1GPR119 | |
| SCHEMBL28674266 | 0.70 | GPR119 (0.45) | GPR119STS | |
| SCHEMBL17129369 | 0.68 | NPC1 (0.61) | GPR119NPC1ALDH1A1MAPTMAPK1 | |
| SCHEMBL4760822 | 0.65 | GPR119 (0.66) | GPR119 | |
| SCHEMBL4675927 | 0.65 | GPR119 (0.50) | GPR119STS | |
| SCHEMBL3249107 | 0.65 | STS (0.58) | GPR119NPC1HTTRAB9ASTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-3896060-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| EP-3896060-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | TRPV1 68/4885GPR119 56/4885NPC1 446/4885 |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | TRPV1 68/4885GPR119 56/4885NPC1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.